AGTC
- Company typePublic
- Founded1999
- HeadquartersAlachua, United States
- Headcount101–250
- GTM typeB2B
- OfferingServices
AGTC firmographics
Firmographics- Name
- AGTC
- Legal name
- Applied Genetic Technologies Corporation
- Website
- https://agtc.com
- Company type
- Public
- Founded year
- 1999
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
AGTC industry classification
Industry- Product category
- Ophthalmology Gene Therapy
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- AAV Vector Gene Therapy Developers (HLAAACAA)
- akta.pro secondary industries
- Ophthalmology Gene Therapies (HLAAACAG), Gene Therapy for Rare/Monogenic Diseases (HLAAACAE), Rare Ophthalmology Disorder Therapies (HLAIAIAK)
Keywords
Where AGTC is headquartered
LocationHeadquarters
- HQ city
- Alachua
- HQ country
- United States
- HQ region
- North America
Markets served
AGTC business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Others
AGTC product offering
Product offeringCore offering
AGTC is a clinical-stage biotechnology company developing AAV (adeno-associated virus) vector-based gene therapies for the treatment of rare and prevalent inherited ocular diseases. The company conducts human clinical trials of gene therapy candidates targeting conditions such as X-linked retinitis pigmentosa (XLRP), dry age-related macular degeneration (dAMD/GA), and cone rod dystrophy (CRD), aiming to deliver single-treatment, long-lasting therapeutic benefit.
Differentiator
Problem solved
Functional benefit
Products and services
- AAV Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP) Investigational AAV-based gene therapy delivering a functional copy of the RPGR gene to treat patients with X-linked retinitis pigmentosa, an inherited retinal degenerative disease causing progressive vision loss.
- AAV Gene Therapy for Dry Age-related Macular Degeneration (dAMD/GA) Investigational AAV gene therapy candidate designed as a single-treatment intervention for geographic atrophy associated with dry age-related macular degeneration.
- AAV Gene Therapy for Cone Rod Dystrophy (CRD) Investigational AAV gene therapy targeting CDHR1-related cone rod dystrophy, an inherited retinal disease causing progressive loss of cone and rod photoreceptor function.
Companies that use AGTC
Customer profileSegments1 record
Ideal customer profiles2 records
AGTC technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AGTC partnerships and signals
Strategic signalScale indicators1 record
Recent moves6 records
Expansion highlights3 records
AGTC competitors and assessment
Company assessmentEmerging players
- Editas Medicine: Clinical-stage genome editing company developing in vivo gene-editing therapies including EDIT-101 for Leber congenital amaurosis (LCA10), an inherited retinal disease. Comparable as a clinical-stage ocular gene-medicine company using viral vector delivery.
- Sangamo Therapeutics: Clinical-stage gene therapy and genome editing company with a portfolio including AAV-delivered zinc finger protein therapies for rare diseases including neurological and ocular indications. Comparable as a small-cap clinical-stage AAV gene therapy peer.
Direct peers
- REGENXBIO: Clinical-stage AAV gene therapy company with a proprietary NAV technology platform developing treatments for retinal diseases (including wet AMD and rare inherited retinopathies) and other indications. Direct peer given shared AAV delivery technology and ophthalmic therapeutic focus.
- Adverum Biotechnologies: Clinical-stage gene therapy company developing AAV-based treatments for ocular diseases including wet AMD and diabetic macular edema. Comparable AAV platform, ophthalmology focus, and clinical-stage development profile to AGTC.
- 4D Molecular Therapeutics: Clinical-stage gene therapy company leveraging a proprietary AAV capsid discovery platform to develop treatments for retinal diseases (including choroideremia and wet AMD) and rare diseases. Direct peer with shared AAV technology focus and ophthalmology pipeline.
- MeiraGTx: Clinical-stage gene therapy company with multiple ocular programs including treatments for X-linked retinitis pigmentosa (same indication as AGTC's laru-zova) and achromatopsia. Direct competitor in AAV ocular gene therapy with parallel R&D infrastructure.
- GenSight Biologics: Clinical-stage gene therapy company developing AAV-based therapies for inherited retinal diseases including Leber hereditary optic neuropathy (LHON) and retinitis pigmentosa. Direct peer in ocular AAV gene therapy targeting rare inherited retinal conditions.
- Krystal Biotech: Commercial-stage gene therapy company with FDA-approved Vyjuvek for dystrophic epidermolysis bullosa and a pipeline of AAV-based therapies for rare diseases. Comparable AAV platform, rare disease focus, and clinical-to-commercial transition profile.
Broad incumbents
- Spark Therapeutics: Developer of Luxturna, the first FDA-approved AAV gene therapy for an inherited retinal disease (RPE65 mutation), making Spark the most direct commercial reference point for AGTC's ocular AAV pipeline. Acquired by Roche in 2019, Spark operates as a broad gene therapy platform player with overlapping ophthalmology focus.
- BioMarin Pharmaceutical: Established rare disease biopharmaceutical company developing AAV gene therapies including Roctavian for hemophilia A. Comparable as a larger rare-disease gene therapy player pursuing AAV-based modalities with regulatory and commercial scale.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
AGTC social profiles
Digital presenceAGTC financial estimates
Financial estimateRevenue estimate
Valuation estimate
AGTC leadership team
Management profileNumber of profiles
Profiles8 records
AGTC funding detail
Funding detailFunding overview
Funding rounds8 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AGTC M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AGTC
What does AGTC do?
AGTC is a clinical-stage biotechnology company developing AAV (adeno-associated virus) vector-based gene therapies for the treatment of rare and prevalent inherited ocular diseases. The company conducts human clinical trials of gene therapy candidates targeting conditions such as X-linked retinitis pigmentosa (XLRP), dry age-related macular degeneration (dAMD/GA), and cone rod dystrophy (CRD), aiming to deliver single-treatment, long-lasting therapeutic benefit.
Is AGTC a public or private company?
AGTC is a public company. It is classified as public and is currently operating.
When was AGTC founded?
AGTC was founded in 1999. It employs 101 to 250 people.
Where is AGTC based?
AGTC is headquartered in Alachua, United States, in the North America region.
Who are AGTC's main competitors?
Emerging players on record are Editas Medicine and Sangamo Therapeutics. Direct peers are REGENXBIO, Adverum Biotechnologies, 4D Molecular Therapeutics, MeiraGTx, GenSight Biologics and Krystal Biotech. Broad incumbents are Spark Therapeutics and BioMarin Pharmaceutical.
Does AGTC have an API?
No public API is recorded for AGTC.
What industry is AGTC in?
AGTC's product category is Ophthalmology Gene Therapy. Its primary akta.pro industry code is HLAAACAA, AAV Vector Gene Therapy Developers, with a secondary code of HLAAACAG, Ophthalmology Gene Therapies. Its NAICS code is 541714 and its SIC code is 2836.